The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents - PubMed
. 2024 Apr;47(4):360-376.
doi: 10.1007/s12272-024-01491-4. Epub 2024 Mar 29.
Wun-A Kook # 1 , Shi-Xun Ma 1 , Bo-Ram Lee 1 , Yong-Hyun Ko 1 , Seon-Kyung Kim 1 , Youyoung Lee 1 , Jae-Gyeong Lee 1 , Sooyeun Lee 2 , Kyeong-Man Kim 3 , Seok-Yong Lee 1 , Choon-Gon Jang 4
Affiliations
- PMID: 38551761
- DOI: 10.1007/s12272-024-01491-4
The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents
Young-Jung Kim et al. Arch Pharm Res. 2024 Apr.
Abstract
Novel psychoactive substances (NPSs) are new psychotropic drugs designed to evade substance regulatory policies. 25E-NBOMe (2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine) has recently been identified as an NPS, and its recreational misuse has been reported to be rapidly increasing. However, the psychopharmacological effects and mechanisms of 25E-NBOMe have not been studied. We examined the abuse potential of 25E-NBOMe using the conditioned place preference in male mice and self-administration paradigms in male rats. Additionally, immunoblot assay, enzyme-linked immunosorbent assay, and microdialysis were used to determine the molecular effects of 25E-NBOMe in the nucleus accumbens (NAc). Our data demonstrated that 25E-NBOMe induces conditioned place preference, and the dopaminergic signaling in the NAc mediates these. Following 25E-NBOMe administration, expression of dopamine transporter and dopamine D1 receptor (D1DR) were enhanced in the NAc of male mice, and NAc dopamine levels were reduced in both male mice and rats. Induction of intracellular dopaminergic pathways, DARPP32, and phosphorylation of CREB in the NAc of male mice was also observed. Significantly, pharmacological blockade of D1DR or chemogenetic inhibition of D1DR-expressing medium spiny neurons in the NAc attenuated 25E-NBOMe-induced conditioned place preference in male mice. We also examined the hallucinogenic properties of 25E-NBOMe using the head twitch response test in male mice and found that this behavior was mediated by serotonin 2A receptor activity. Our findings demonstrate that D1DR signaling may govern the addictive potential of 25E-NBOMe. Moreover, our study provides new insights into the potential mechanisms of substance use disorder and the improvement of controlled substance management.
Keywords: 25E-NBOMe; Dopamine D1 receptor; Hallucinogenic effect; Novel psychoactive substance; Reward.
© 2024. The Pharmaceutical Society of Korea.
Similar articles
-
Custodio RJP, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, Lee HJ, Yoo SY, Lee KW, Lee YS, Seo JW, Ryu IS, Kim HJ, Cheong JH. Custodio RJP, et al. Addict Biol. 2020 Nov;25(6):e12850. doi: 10.1111/adb.12850. Epub 2019 Nov 20. Addict Biol. 2020. PMID: 31749223
-
A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents.
Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, Kim SK, Kim SE, Lee YS, Kim HC, Lee SY, Jang CG. Seo JY, et al. Brain Res Bull. 2019 Oct;152:19-26. doi: 10.1016/j.brainresbull.2019.07.002. Epub 2019 Jul 4. Brain Res Bull. 2019. PMID: 31279579
-
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A. Eshleman AJ, et al. Biochem Pharmacol. 2018 Dec;158:27-34. doi: 10.1016/j.bcp.2018.09.024. Epub 2018 Sep 25. Biochem Pharmacol. 2018. PMID: 30261175 Free PMC article.
-
Lee JG, Hur KH, Hwang SB, Lee S, Lee SY, Jang CG. Lee JG, et al. ACS Chem Neurosci. 2023 Aug 2;14(15):2658-2666. doi: 10.1021/acschemneuro.3c00196. Epub 2023 Jul 18. ACS Chem Neurosci. 2023. PMID: 37463338
-
Jiang SZ, Sweat S, Dahlke SP, Loane K, Drossel G, Xu W, Tejeda HA, Gerfen CR, Eiden LE. Jiang SZ, et al. J Neurosci. 2021 Jan 27;41(4):711-725. doi: 10.1523/JNEUROSCI.1497-20.2020. Epub 2020 Dec 2. J Neurosci. 2021. PMID: 33268547 Free PMC article.
References
-
- Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11(8):932–939. https://doi.org/10.1038/nn.2153 - DOI - PubMed - PMC
-
- Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217. https://doi.org/10.1124/pr.110.002642 - DOI - PubMed
-
- Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Hervé D, Valjent E, Girault JA (2008) Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28(22):5671–5685. https://doi.org/10.1523/JNEUROSCI.1039-08.2008 - DOI - PubMed - PMC
-
- Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F (2005) The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95(6):1597–1607. https://doi.org/10.1111/j.1471-4159.2005.03485.x - DOI - PubMed
-
- Bubar MJ, Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6(18):1971–1985. https://doi.org/10.2174/156802606778522131 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources